Ophir Shahaf - Short Bio (2023)

Mr. Shahaf trained as a corporate lawyer at Tel Aviv University and completed his MBA at the Stern School of Business (NYU), majored in Finance & International Business. He was part of the founding team at **Clal Biotechnology Industries,** the first Israeli institutional investor in Life Sciences in Israel, taken public (TASE:CBI**)** with several exits of portfolio companies (Compugen, Mediwound).

Served as VP BD at **Protalix**, raised funds and entered into a partnership with Pfizer, before going public (NYSE:PLX). Was a founder and CEO at **Hadasit Bio-Holdings** (TASE:HBL), the Technology Transfer Office of the Hadassah Medical Center in Jerusalem. Led the company and portfolio during IPO + subsequent rounds of financing (totaling approx. $ 25 M), via Convertible Bonds, PIPE's and secondary offerings.

Was part of the founding team and currently a partner at **eHealth Ventures**, a partnership including an incubator and 2 VC funds. eHV is a leading investor in early-stage Digital Health companies in Israel, with a focus on Digital Diagnostics, Therapeutics and home care and a portfolio of 25 investments. Manages deal flow (over 1600 companies in 5 years), and responsible for market analysis, due diligence, negotiation and closing of transactions. Serves on the board of portfolio companies, as well as a TASE public company.

A native English speaker with legal, financial and scientific education, and over 20 years of
experience working within the life science industry.